In this episode, Martin discusses a sharp decline in IBM and considers what it could mean for the broader technology sector. He also provides an analysis of Lumentum (LITE), examining the company's business, competitive position, and outlook, before discussing Adobe's recent stock performance and the factors he believes are contributing to its relative strength.

In this episode, Martin provides an extended analysis of Insmed, examining the company’s commercial products, clinical pipeline, competitive position, and potential growth opportunities. He also discusses the assumptions behind the company’s valuation, the risks surrounding its drug-development programs, and the factors that could shape the stock’s longer-term outlook.

In this episode, Martin discusses recent weakness in IBM and considers whether it could signal broader challenges for other companies in the sector. He also provides a detailed analysis of Bristol Myers Squibb (BMY), examining its business, product portfolio, and valuation, before reviewing Insmed (INSM) and sharing his perspective on the company's prospects and investment outlook.

In this episode, Martin discusses a potential short opportunity involving Bristol Myers Squibb, explaining the factors that have led him to view the company more cautiously. He examines the business, product portfolio, valuation, and competitive landscape, outlining the reasoning behind his investment thesis and the risks he believes investors should consider.

In this episode, Martin discusses a company or market trend that he believes may be approaching a turning point and explains the reasoning behind his outlook. He also examines recent trading activity in Q32 Bio, analyzes Micron’s position in the semiconductor market, and reviews Agenus and Abivax, discussing their pipelines, valuations, and the factors shaping his investment perspective on each company.

In this episode, Martin discusses a market trend that he believes may be nearing its end and explains the reasoning behind that view. He also shares his perspective on SanDisk, outlines his thesis for a short position in Analog Devices, and evaluates Fable, explaining why he has a negative outlook on the company and its prospects.

This compilation brings together Martin’s discussions on how financial markets have evolved and why trading strategies that were successful in the 1990s may be less effective today. Across a range of clips, he examines changes in market structure, technology, quantitative investing, and competition, while sharing his perspective on the skills and approaches he believes are most important for adapting to modern markets.

In this episode, Martin discusses two short positions that he says have reached their objectives and explains why he is taking profits. He also shares signals generated by his quantitative investment model, highlighting two stocks that it currently identifies as long opportunities and discussing the factors behind those selections and how they fit into his broader investment approach.

In this episode, Martin discusses his view that advances in AI could fundamentally reshape the software-as-a-service (SaaS) industry over the coming years. He explains the reasoning behind this thesis, examines the potential impact of AI agents on software businesses, and shares his perspectives on HubSpot, CAPR, and Nvidia, discussing how these companies may be affected by changing technology trends and evolving market conditions.

In this episode, Martin challenges a market narrative that he believes investors should view with skepticism before explaining his reasoning. He also analyzes Analog Devices (ADI), discusses his bullish outlook on Google, and shares his views on Oracle and Palantir, examining their valuations, competitive positions, and the factors influencing his investment outlook for each company.